Indian pharma companies are betting on Chinese partnerships to bring oral GLP-1 drugs to market, but the window to act is ...

Semaglutide and tirzepatide telehealth access, compounded GLP-1 program pricing, refund terms, and weight loss medication ...

Novo Nordisk’s phase 3a PIONEER TEENS trial found its oral semaglutide pill significantly improved blood sugar control in children and adolescents with type 2 diabetes compared to placebo. The ...

GLP-1-A26-2 Amycretin and retatrutide to be tested for compatibility with DehydraTECH KELOWNA, BC / ACCESS Newswire / April 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or ...

Novo Nordisk A/S NVO reported positive topline results from its late-stage PIONEER TEENS trial, showing that oral semaglutide ...

Him & Hers announced Thursday that eligible users can now access the full r | Providers can now send prescriptions of Eli ...

Armed with new phase 3 data, Novo Nordisk has said it will file for approval of oral formulations of its GLP-1 agonist ...

April 23 (Reuters) - Novo Nordisk's oral GLP-1 drug significantly lowered blood sugar levels in children and adolescents with ...

Novo Nordisk said April 23 it plans to seek expanded FDA approval for its Ozempic pill in the second half of 2026, which would make the drug the first oral GLP-1 approved for children and adolescents ...

Novo Nordisk (NVO) stock gains after oral semaglutide pill succeeds in pediatric type 2 diabetes trial. Company targets H2 ...

Novo Nordisk (NVO) stock is in focus as the company plans to launch Ozempic pill for children with type 2 diabetes after a ...

Drugmakers continue to test weight-loss medicines against dummy pills and shots, even with a growing number of effective approved obesity drugs. This practice raises practical questions.